

Schrodinger, Inc. (SDGR)

Nasdaq: healthcare: SIC 2834, Pharmaceutical Preparations: CIK 0001490978

Schrodinger, Inc. SDGR; healthcare	
Grade	C A B C D E middle fifth of 371 graded peers percentile 51.1; sampling error 2.5 points; lower is stronger
Rank	190 of 371
Profitability	C percentile 57.0
Solvency	C percentile 48.4
Growth and financing	B/C percentile 40.0
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$726.2M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress, fortress balance sheet
Inputs computable	8 of 14
Graded from	filings received through Feb 25, 2026 226 days before the rescan; latest periodic filing 10-Q received Aug 5, 2026
Last close	\$26.40 2026-10-08; market equity \$1.7B
Price used in grade	None



C, the tortoise
middle fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescan

split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: C/D from Mar 21, 2024, C from Apr 21, 2024, C/D from Mar 21, 2025

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 25, 2026

We are transforming the way therapeutics and materials are discovered. Our differentiated, physics-based computational platform enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at a lower cost, compared to traditional methods. Our software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. We are applying our computational platform to advance a broad pipeline

of drug discovery programs in collaboration with leading biopharmaceutical companies.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 57.0						
Gross profitability		19.6%	32.2%	64.4	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(15.1%)	(6.6%)	29.6	811	2025-12-31
Gross margin stability, five years		6.3 pts	2.8 pts	76.9	243	2025-12-31
Solvency, sleeve percentile 48.4						
Twelve-month failure probability		not computable	0.07%			liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-prime		(0.33)	(0.31)	37.9	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		2.75x	2.96x	58.9	839	2025-12-31
Growth and financing, sleeve percentile 40.0						
Revenue growth, three-year compound		12.2%	10.0%	45.2	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000 pretax income must exceed the validity floor and imply a 0%-100% tax rate
Reinvestment rate		not computable	37.1%			
Asset growth, three years		1.8%	2.1%	47.5	704	2025-12-31
Net share issuance, one year		1.3%	2.5%	27.2	634	2023-12-31

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
185	Neogen Corp. (NEOG)	49.7	C	late filer
186	Nurix Therapeutics, Inc. (NRIX)	50.0	C	dilution, short runway
187	Pacira BioSciences, Inc. (PCRX)	50.3	C	
188	Neuroone Medical Technologies Corp. (NMTC)	50.5	C	short runway, fortress balance sheet
189	RadNet, Inc. (RDNT)	50.8	C	
190	Schrodinger, Inc. (SDGR) <	51.1	C	
191	Zai Lab Ltd. (ZLAB)	51.4	C	
192	Recursion Pharmaceuticals, Inc. (RXRX)	51.6	C	dilution, fortress balance sheet
193	Haemonetics Corp. (HAE)	51.9	C	
194	Solventum Corp. (SOLV)	52.2	C	
195	Aveanna Healthcare Holdings, Inc. (AVAH)	52.4	C	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(2.8%)	8.0%	45
Distance from 52-week high	(19.0%)	(31.4%)	66
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	0.7%	(1.0%)	59
Book value to price	0.20	0.28	40
Sales to price	0.15	0.31	34
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(0.24)	(0.14)	45

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$287.9M

Operating cash flow, four quarters	-\$126.9M
Months of runway	27.2
Days since last periodic filing	65 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	\$20.0M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$142.6M	2025-12-31	2026-02-25	10-K	0001490978-26-000010
2	assets	us-gaap:Assets	\$726.2M	2025-12-31	2026-02-25	10-K	0001490978-26-000010
3	net income	us-gaap:NetIncomeLoss	-\$103.3M	2025-12-31	2026-02-25	10-K	0001490978-26-000010
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$13.9M	2025-12-31	2026-02-25	10-K	0001490978-26-000010
5	assets	us-gaap:Assets	\$823.2M	2024-12-31	2026-02-25	10-K	0001490978-26-000010
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$255.9M	2025-12-31	2026-02-25	10-K	0001490978-26-000010
7	gross profit	us-gaap:GrossProfit	\$132.1M	2024-12-31	2026-02-25	10-K	0001490978-26-000010
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$207.5M	2024-12-31	2026-02-25	10-K	0001490978-26-000010
9	gross profit	us-gaap:GrossProfit	\$140.7M	2023-12-31	2026-02-25	10-K	0001490978-26-000010
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$216.7M	2023-12-31	2026-02-25	10-K	0001490978-26-000010
11	gross profit	us-gaap:GrossProfit	\$101.0M	2022-12-31	2025-02-26	10-K	0001490978-25-000014
12	revenue	us-gaap:Revenues	\$181.0M	2022-12-31	2025-02-26	10-K	0001490978-25-000014
13	gross profit	us-gaap:GrossProfit	\$65.6M	2021-12-31	2024-02-28	10-K	0001490978-24-000018
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$137.9M	2021-12-31	2024-02-28	10-K	0001490978-24-000018
15	current assets	us-gaap:AssetsCurrent	\$519.3M	2025-12-31	2026-02-25	10-K	0001490978-26-000010
16	current liabilities	us-gaap:LiabilitiesCurrent	\$189.1M	2025-12-31	2026-02-25	10-K	0001490978-26-000010
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$628.8M	2025-12-31	2026-02-25	10-K	0001490978-26-000010
18	operating income	us-gaap:OperatingIncomeLoss	-\$166.9M	2025-12-31	2026-02-25	10-K	0001490978-26-000010
19	book equity	us-gaap:StockholdersEquity	\$364.1M	2025-12-31	2026-02-25	10-K	0001490978-26-000010
20	liabilities	us-gaap:Liabilities	\$362.1M	2025-12-31	2026-02-25	10-K	0001490978-26-000010
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.4M	2025-12-31	2026-02-25	10-K	0001490978-26-000010
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$157.4M	2024-12-31	2026-02-25	10-K	0001490978-26-000010
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$7.3M	2024-12-31	2026-02-25	10-K	0001490978-26-000010
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$136.7M	2023-12-31	2026-02-25	10-K	0001490978-26-000010
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$13.4M	2023-12-31	2026-02-25	10-K	0001490978-26-000010
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$119.7M	2022-12-31	2025-02-26	10-K	0001490978-25-000014
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$8.0M	2022-12-31	2025-02-26	10-K	0001490978-25-000014
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$6.0M	2025-12-31	2026-02-25	10-K	0001490978-26-000010
29	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$114.5M	2025-12-31	2026-02-25	10-K	0001490978-26-000010
30	income tax	us-gaap:IncomeTaxExpenseBenefit	\$939,000	2025-12-31	2026-02-25	10-K	0001490978-26-000010
31	current assets	us-gaap:AssetsCurrent	\$635.0M	2024-12-31	2026-02-25	10-K	0001490978-26-000010
32	current liabilities	us-gaap:LiabilitiesCurrent	\$191.7M	2024-12-31	2026-02-25	10-K	0001490978-26-000010
33	assets	us-gaap:Assets	\$803.0M	2023-12-31	2025-02-26	10-K	0001490978-25-000014
34	assets	us-gaap:Assets	\$688.6M	2022-12-31	2024-02-28	10-K	0001490978-24-000018
35	shares outstanding	us-gaap:CommonStockSharesOutstanding	62,977,316	2023-12-31	2024-02-28	10-K	0001490978-24-000018
36	shares outstanding	us-gaap:CommonStockSharesOutstanding	62,163,739	2022-12-31	2024-02-28	10-K	0001490978-24-000018